H.C. Wainwright maintains Buy rating on Abeona Therapeutics stock despite FDA setback

Abeona Therapeutics received a Complete Response Letter (CRL) from the FDA for its gene therapy UX111, citing chemistry, manufacturing, and controls (CMC) issues and facility observations, not clinical data, requiring a resubmission with an estimated six-month review period. Despite this regulatory delay, the company significantly strengthened its financial position by selling a Priority Review Voucher for $155 million, securing over two years of operating capital, and concurrently gained FDA approval for its ZEVASKYN therapy, with first patient treatment anticipated in Q3 2025. Analysts, including H.C. Wainwright, maintain positive ratings, highlighting the company's enhanced liquidity and strategic advancements which mitigate the UX111 setback and support its long-term prospects.

Analysis

Abeona Therapeutics (ABEO) faces a regulatory delay for its gene therapy UX111 after receiving a Complete Response Letter (CRL) from the FDA. The setback, however, is significantly mitigated by its nature; the FDA's concerns are centered on Chemistry, Manufacturing, and Controls (CMC) and facility inspections, not on the clinical data package, which the agency acknowledged as robust. This suggests the therapy remains 'eminently approvable' according to H.C. Wainwright, with a potential six-month review period following resubmission. More critically, this delay is overshadowed by two major positive catalysts. First, the company secured FDA approval for ZEVASKYN, its cell-based gene therapy, with the first patient treatment expected in Q3 2025. Second, Abeona fortified its balance sheet by selling a Priority Review Voucher for $155 million, boosting its cash and investments to $225 million. This provides over two years of operating capital, directly addressing the noted risk of rapid cash burn and strengthening its liquidity, reflected in a current ratio of 4.9x. Analyst sentiment remains strongly positive, with H.C. Wainwright and Stifel maintaining Buy ratings and $20 price targets, indicating that the core investment thesis is unaffected by the UX111 CRL.

Key Decisions for Investors

• Investors should weigh the manageable, non-clinical regulatory delay for UX111 against the significant de-risking achieved through the full FDA approval of ZEVASKYN and the securing of a multi-year capital runway from the $155 million PRV sale.
• Given the substantial disconnect between the current trading price of $5.74 and the analyst consensus price targets around $20, positions could be considered based on the valuation of the now-approved ZEVASKYN asset and the strengthened balance sheet, independent of the delayed UX111.
• Key catalysts to monitor are the successful resubmission of the UX111 application and any execution updates regarding the commercial launch of ZEVASKYN, which is anticipated to generate revenue in the latter half of 2025.